CELC · Celcuity Inc
Price
Snapshot
50 fields · last close| Market Cap | $2.77B |
| P/E | — |
| Float | 40.66M |
| Beta | 0.13 |
| Volatility | 5.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 62.0 |
| Price | 58.46 |
| Change | +3.32% |
| Prev Close | 56.58 |
| Open | 60.16 |
| Day Low | 53.54 |
| Day High | 60.23 |
| Avg Vol | 2 |
| Avg $ Vol | $123.1M |
| 52W High | 151.02 |
| 52W Low | 49.80 |
| 52W Pos | 8.6% |
| From High | −61.29% |
| From Low | +17.39% |
| Max DD 1Y | −60.97% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −18.98% |
| SMA 50 | −29.47% |
| SMA 200 | −43.05% |
| RSI (14) | 21.8 |
| Vol 30D | 49.8% |
| Vol 90D | 62.6% |
| 1Y Range | 50–151 |
| Daily bars | 536 |
| Perf Week | −16.72% |
| Perf Month | −33.36% |
| Perf Quarter | −35.70% |
| Perf Half Y | −53.80% |
| Perf Year | +13.09% |
| Perf YTD | −41.86% |
| Prev Day | +3.32% |
| Clavix | C+ |
| Debt / Eq | 1.37 |
| Curr Ratio | 10.55 |
| Int Cover | -34.8× |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Mixed |
| Leverage | Very High |
| Sector rank | 25 / 35 |
Clavix risk grade
regraded every trading dayCELC grades C+, 62.0 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (42, fragile). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 25 of 35 in Biotechnology by Clavix score.
How rough the ride is
| CELC | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.13 | 0.51 |
| Volatilityannualized | 5.0% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −61.0% | — |
| Typical daily movemedian absolute daily change | 2.25% | — |
| Days beyond ±3%of the last 252 sessions | 95 (38%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CELC | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.13 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CELC | |
|---|---|
| 1 week | −16.7% |
| 1 month | −33.4% |
| Year to date | −41.9% |
| 1 year | +13.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CELC | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 24 Jul |
| Average score0 most bearish, 100 most bullish | 65 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 4 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| CELC | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openZacks Research lowered its rating on Celcuity (CELC) from hold to strong sell in a report issued Tuesday.
Celcuity announced its drug REVTORPYK (gedatolisib) is now available for sale in the US to certain advanced breast cancer patients, and also filed a supplemental application that could let doctors prescribe it to more patients. The stock fell 17.3%. No specific catalyst was identified.
Celcuity announced it will give one oral presentation and three poster presentations at the European Society for Medical Oncology (ESMO) Congress in Madrid, October 23-27, 2026. The presentations will feature data from clinical trials of its drug gedatolisib in HR+/HER2- advanced breast cancer and metastatic castration-resistant prostate cancer (mCRPC).
Celcuity launched its drug REVTORPYK in the US for certain advanced breast cancer patients, alongside a patient support program, and added finance leader David W. Gryska to its board. Despite these milestones, shares pulled back, with a 25.1% decline over 30 days, though the 1-year return is still up 42.7%. The article is cut off before identifying any specific cause for the recent price decline.
Celcuity appointed David Gryska, former CFO of Incyte and Celgene, to its Board of Directors, bringing over 35 years of financial and strategic leadership in life sciences as the company transitions to commercial-stage operations following its first FDA approval of REVTORPYK.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ERAS | Erasca Inc | C | $4.68B | — | 0.67 | Compare |
| PTCT | PTC Therapeutics Inc | B | $4.94B | 7.24 | 0.51 | Compare |
| CGON | CG Oncology Inc | B- | $5.31B | — | 0.31 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $6.17B | — | 0.77 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $7.14B | — | 0.39 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $7.90B | — | 1.36 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.26B | 18.71 | 1.83 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $8.33B | 100.49 | 1.20 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.